非何杰金氏淋巴瘤市场：KOL 洞察

本报告考察了非何杰金氏淋巴瘤市场，并对目前和新兴的治疗方法进行了详细分析。包含 CAR T 细胞疗法、双特异性抗体和 BTK 抑制剂的功效和未来潜力的重要见解。 也讨论非何杰金氏淋巴瘤治疗的最新趋势、挑战和进展，为医疗保健专业人员和研究人员提供有价值的资讯。

目录

执行摘要

目前与未来的治疗演算法

研究目的

CAR T 细胞疗法

• 瀰漫性大 B 细胞淋巴瘤
  • Yescarta（axicabtagene ciloleucel，Gilead）、Bryanzi（lisocabtagene maraleucel，BMS）和 Kymriah（tisagenlecleucel、Novartis）
• 滤泡性淋巴瘤
  • Yescarta（axicabtagene ciloleucel，Gilead）、Bryanzi（lisocabtagene maraleucel，BMS）和 Kymriah（tisagenlecleucel，Novartis）
• 套细胞淋巴瘤
  • Tecartas（Brexacabtagene Autoleucel，Gilead）和 Breyanzi（Lysocabtagene Malaleucel，BMS）
• 下一代 CAR T 细胞疗法
  • 主要见解摘要

作用于 T 细胞的双特异性抗体（BsAb）

• 滤泡性淋巴瘤
  • Lunumio（mosnetuzumab，Roche）、Epkinly/Tepkinly（epcolitamab、AbbVie/Genmab）、Columvi（grofitamab，Roche）和 odronectamab（Regeneron）
• 瀰漫性大 B 细胞淋巴瘤
  • Epkinly/Tepkinly（epcolitamab、AbbVie/Genmab）、Columvi（grofitamab、Roche）、Lunsmio（mosnetuzumab、Roche）和 odronectamab（Regeneron）
• 套细胞淋巴瘤与边缘区淋巴瘤
  • Epkinly/Tepkinly（epcolitamab、AbbVie/Genmab）、Columvi（grofitamab、Roche）、Lunsmio（mosnetuzumab、Roche）和 odronectamab（Regeneron）

抗体药物偶联物（ADC）

• 核准的药物
  • Polyvy（polatuzumab vedotin，Roche）
  • Zinlonta（loncasuximab tesirin，ADC Therapeutics/Sobi）

单株抗体（mAb）

• 核准的药物
  • Monjuvi/Minjuvi（tafasitamab、Incyte）

BCL-2 抑制剂（9）

• 研究药物
  • Venclexta/Venclyxt（Venetoclax、AbbVie/Roche）

BTK 抑制剂（16）

• 核准的药物（16）
  • Brukinsa（zanubrutinib，BeiGene）、Calquence（acalabrutinib，AstraZeneca）、Imbruvica（ibrutinib，AbbVie/J&J）和 Jaypirca（pirtobrutinib，Lilly）

未来治疗趋势

• 主要见解摘要

附录

KOL报表

This Non-Hodgkin's Lymphoma (NHL) Therapy Trends report provides a detailed analysis of current and emerging therapies. It includes insights from leading Key Opinion Leaders (KOLs) on the efficacy and future potential of CAR T-cell therapy, bispecific antibodies, and BTK inhibitors. The report examines the latest trends, challenges, and advancements in NHL treatment, offering valuable information for healthcare professionals and researchers. It aims to inform on the evolving landscape of NHL management, supported by data-driven findings and expert opinions.

Table of Contents

Executive summary

Current and future treatment algorithms

Research objectives

CAR T-cell therapies

• Diffuse large B-cell lymphoma
  • Yescarta (axicabtagene ciloleucel; Gilead), Breyanzi (lisocabtagene maraleucel; BMS) and Kymriah (tisagenlecleucel; Novartis)
• Follicular lymphoma
  • Yescarta (axicabtagene ciloleucel; Gilead), Breyanzi (lisocabtagene maraleucel; BMS) and Kymriah (tisagenlecleucel; Novartis)
• Mantle cell lymphoma
  • Tecartus (brexucabtagene autoleucel; Gilead) and Breyanzi (lisocabtagene maraleucel; BMS)
• Next-generation CAR T-cell therapies
  • Key insights summary

T cell-engaging bispecific antibodies (BsAbs)

• Follicular lymphoma
  • Lunsumio (mosunetuzumab; Roche), Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche) and odronextamab (Regeneron)
• Diffuse large B-cell lymphoma
  • Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche), Lunsumio (mosunetuzumab; Roche), and odronextamab (Regeneron)
• Mantle cell lymphoma and marginal zone lymphoma
  • Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche), Lunsumio (mosunetuzumab; Roche) and odronextamab (Regeneron)

Antibody-drug conjugates (ADCs)

• Approved drugs
  • Polivy (polatuzumab vedotin; Roche)
  • Zynlonta (loncastuximab tesirine; ADC Therapeutics/Sobi)

Monoclonal antibodies (mAbs)

• Approved drugs
  • Monjuvi/Minjuvi (tafasitamab; Incyte)

BCL-2 inhibitors

• Pipeline drugs
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche)

BTK inhibitors

• Approved drugs
  • Brukinsa (zanubrutinib; BeiGene), Calquence (acalabrutinib; AstraZeneca), Imbruvica (ibrutinib; AbbVie/J&J) and Jaypirca (pirtobrutinib; Lilly)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe

KOL Bulletins